Trial Profile
Patient Preferences for Treatments for Hepatocellular Cancer (HCC) in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 27 Oct 2016 Status changed from recruiting to completed.
- 02 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 02 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.